Biosafety Management Based Upon Risk Assessment and Monitoring: Perspectives from a Clinical Laboratory, China.

IF 4.6 Q2 MATERIALS SCIENCE, BIOMATERIALS
ACS Applied Bio Materials Pub Date : 2024-09-26 eCollection Date: 2024-01-01 DOI:10.2147/RMHP.S476005
Qizhi Diao, Yongpei Long, Fangyu Yang, Cuihui Nong, Huamiao Tang, Xiangmin Zhou, Guoqiang Zhu, Qiang Ding
{"title":"Biosafety Management Based Upon Risk Assessment and Monitoring: Perspectives from a Clinical Laboratory, China.","authors":"Qizhi Diao, Yongpei Long, Fangyu Yang, Cuihui Nong, Huamiao Tang, Xiangmin Zhou, Guoqiang Zhu, Qiang Ding","doi":"10.2147/RMHP.S476005","DOIUrl":null,"url":null,"abstract":"<p><strong>Background and objective: </strong>Inadequate risk assessment and a lack of risk monitoring are common deficiencies in clinical laboratory, and are also the main causes of biosafety incidents. Therefore, we summarized the experience of implementing adequate risk assessment and maintaining risk monitoring, and established a procedure for continuously improving biosafety management.</p><p><strong>Methods: </strong>Learning from our laboratory's experience in implementing risk assessment, risk response, and risk monitoring before and during the COVID-19 epidemic, we summarized the procedures for fully identifying risks, accurately evaluating risks, maintaining risk monitoring, establishing and regular reviewing safety indicators. On this basis, we established a system for continuously improving biosafety management through risk monitoring and reviewing safety indicator.</p><p><strong>Results: </strong>We identified a total of 30 unacceptable risks prior to the COVID-19 pandemic, and developed and implemented appropriate risk control measures. After risk control, residual risks were acceptable, and no biosafety incidents have occurred. During the COVID-19 pandemic, after multiple risk monitoring, we identified ten new risks, three ineffective risk control measures, and multiple control measures for excessive protection. Then, we timely adjusted risk control measures to avoid laboratory personnel infection and excessive protection. Meanwhile, We established eight safety indicators and identified two improvement opportunities through regular reviews.</p><p><strong>Conclusion: </strong>Adequate risk identification and accurate risk assessment are particularly important for effectively controlling biosafety risks. Biosafety management should be continuously improved to deal with ineffective and excessive protection caused by various changes in experimental activities. Continuous improvement of biosafety management can be achieved through risk monitoring, regular review of safety indicators, and management reviews. This study will help laboratory managers to fully and accurately assess risks, as well as update risks and their control measures through risk monitoring, and the continuous improvement procedure established in the study has certain reference value for laboratories to effectively respond to emerging infectious diseases and avoid excessive protection.</p>","PeriodicalId":2,"journal":{"name":"ACS Applied Bio Materials","volume":null,"pages":null},"PeriodicalIF":4.6000,"publicationDate":"2024-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11444055/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Applied Bio Materials","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/RMHP.S476005","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"MATERIALS SCIENCE, BIOMATERIALS","Score":null,"Total":0}
引用次数: 0

Abstract

Background and objective: Inadequate risk assessment and a lack of risk monitoring are common deficiencies in clinical laboratory, and are also the main causes of biosafety incidents. Therefore, we summarized the experience of implementing adequate risk assessment and maintaining risk monitoring, and established a procedure for continuously improving biosafety management.

Methods: Learning from our laboratory's experience in implementing risk assessment, risk response, and risk monitoring before and during the COVID-19 epidemic, we summarized the procedures for fully identifying risks, accurately evaluating risks, maintaining risk monitoring, establishing and regular reviewing safety indicators. On this basis, we established a system for continuously improving biosafety management through risk monitoring and reviewing safety indicator.

Results: We identified a total of 30 unacceptable risks prior to the COVID-19 pandemic, and developed and implemented appropriate risk control measures. After risk control, residual risks were acceptable, and no biosafety incidents have occurred. During the COVID-19 pandemic, after multiple risk monitoring, we identified ten new risks, three ineffective risk control measures, and multiple control measures for excessive protection. Then, we timely adjusted risk control measures to avoid laboratory personnel infection and excessive protection. Meanwhile, We established eight safety indicators and identified two improvement opportunities through regular reviews.

Conclusion: Adequate risk identification and accurate risk assessment are particularly important for effectively controlling biosafety risks. Biosafety management should be continuously improved to deal with ineffective and excessive protection caused by various changes in experimental activities. Continuous improvement of biosafety management can be achieved through risk monitoring, regular review of safety indicators, and management reviews. This study will help laboratory managers to fully and accurately assess risks, as well as update risks and their control measures through risk monitoring, and the continuous improvement procedure established in the study has certain reference value for laboratories to effectively respond to emerging infectious diseases and avoid excessive protection.

基于风险评估和监测的生物安全管理:来自中国临床实验室的视角。
背景和目的:风险评估不足和缺乏风险监控是临床实验室普遍存在的缺陷,也是导致生物安全事故的主要原因。因此,我们总结了实施充分的风险评估和保持风险监控的经验,并建立了持续改进生物安全管理的程序:方法:借鉴本实验室在 COVID-19 疫情发生前和发生期间实施风险评估、风险应对和风险监控的经验,总结出充分识别风险、准确评估风险、保持风险监控、建立和定期审查安全指标的程序。在此基础上,我们建立了一套通过风险监控和审查安全指标来持续改进生物安全管理的系统:结果:在 COVID-19 大流行之前,我们共发现了 30 个不可接受的风险,并制定和实施了适当的风险控制措施。风险控制后,剩余风险是可接受的,没有发生生物安全事故。在 COVID-19 大流行期间,经过多次风险监测,我们发现了 10 个新风险、3 个无效的风险控制措施和多个过度保护的控制措施。随后,我们及时调整了风险控制措施,避免了实验室人员感染和过度防护。同时,我们建立了八项安全指标,并通过定期审查确定了两个改进机会:结论:充分的风险识别和准确的风险评估对于有效控制生物安全风险尤为重要。结论:充分的风险识别和准确的风险评估对于有效控制生物安全风险尤为重要,应不断改进生物安全管理,以应对因实验活动的各种变化而导致的无效保护和过度保护。生物安全管理的持续改进可以通过风险监测、定期审查安全指标和管理评审来实现。本研究有助于实验室管理人员全面、准确地评估风险,并通过风险监测及时更新风险及其控制措施,研究中建立的持续改进程序对实验室有效应对新发传染病、避免过度防护具有一定的参考价值。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
ACS Applied Bio Materials
ACS Applied Bio Materials Chemistry-Chemistry (all)
CiteScore
9.40
自引率
2.10%
发文量
464
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信